

Triplex Formation by an Oligodeoxyribonucleotide Containing *N*⁴-(6-Aminopyridinyl)-2'-deoxycytidine

Chin-Yi Huang and Paul S. Miller*

Department of Biochemistry
School of Hygiene and Public Health
The Johns Hopkins University
Baltimore, Maryland 21205

Received August 9, 1993

A number of laboratories have reported on the abilities of nucleoside analogs and their derivatives to support triplex formation between an oligonucleotide third strand and duplex DNA.¹ Here we demonstrate that oligopyrimidine I carrying *N*⁴-(6-aminopyridinyl)-2'-deoxycytidine (**1**) can form stable triplexes with DNA duplex II-III. The 3',5'-di-*O*-acetyl derivative of **1** was prepared by refluxing 4-(1,2,4-triazol-1-yl)-1-(β-D-3,5-di-*O*-acetylribofuranosyl)pyrimidin-2(1*H*)-one² with 2,6-diaminopyridine in pyridine for 3 days.³ This nucleoside was converted to the *N*-benzoyl-5'-*O*-dimethoxytrityl-3'-*O*-β-cyanoethyl-*N*,*N*-diisopropylphosphoramidite, which was used to prepare I by standard phosphoramidite procedures.⁴ In addition to nucleoside **1**, oligopyrimidine I contained thymidine and 5-methyl-2'-deoxycytidine (C).

Figure 1 shows absorbance versus temperature profiles of solutions containing equimolar concentrations of oligomers I, II, and III. The biphasic curves are indicative of triplex formation, where the first transition corresponds to melting of strand I. This interpretation was confirmed by CD spectroscopy. The CD spectra of triplexes I-II-III(1-A-T) and I-II-III(1-C-G) at 10 °C showed a characteristic reduction of Δε at 220 and 280 nm relative to the calculated Δε for II-III and noninteracting I.^{11,5} At 40 °C, a temperature at which the triplex has melted but the duplex is still intact, the observed spectra were identical to the calculated sum of the spectra of I and duplex II-III.

Triplexes of different stabilities were observed with each base pair combination at position X·Y of duplex II-III(X·Y). The *T*_m's for I-II-III(1-A-T), 32 °C, and I-II-III(1-C-G), ~36 °C, were 12–14 °C higher than those observed for I-II-III(1-T-A) or

(1) (a) Young, S. L.; Krawczyk, S. J.; Matteucci, M. D.; Toole, J. J. *Proc. Natl. Acad. Sci. U.S.A.* **1991**, *88*, 10023–10026. (b) Ono, A.; Ts'o, P.; Kan, L.-S. *J. Am. Chem. Soc.* **1991**, *113*, 4032–4033. (c) Ono, A.; Ts'o, P. O. P.; Kan, L. S. *J. Org. Chem.* **1992**, *57*, 3225–3230. (d) Griffin, L. C.; Kiessling, L. L.; Beal, P. A.; Gillespie, P.; Dervan, P. B. *J. Am. Chem. Soc.* **1992**, *114*, 7976–7982. (e) Koh, J. S.; Dervan, P. B. *J. Am. Chem. Soc.* **1992**, *114*, 1470–1478. (f) Froehler, B. C.; Ricca, D. J. *J. Am. Chem. Soc.* **1992**, *114*, 8320–8322. (g) Krawczyk, S. H.; Milligan, J. F.; Wadwani, S.; Moulds, C.; Froehler, B. C.; Matteucci, M. D. *Proc. Natl. Acad. Sci. U.S.A.* **1992**, *89*, 3761–3764. (h) Froehler, B.; Wadwani, S.; Terhorst, T.; Gerrard, S. *Tetrahedron Lett.* **1992**, *33*, 5307–5310. (i) Miller, P. S.; Bhan, P.; Cushman, C. D.; Trapani, T. L. *Biochemistry* **1992**, *31*, 6788–6793. (j) Stiltz, H. U.; Dervan, P. B. *Biochemistry* **1993**, *32*, 2177–2185. (k) Milligan, J. F.; Krawczyk, S. H.; Wadwani, S.; Matteucci, M. D. *Nucleic Acids Res.* **1993**, *21*, 327–333. (l) Jetter, M. C.; Hobbs, F. W. *Biochemistry* **1993**, *32*, 3249–3254. (m) Davison, E. C.; Johnson, K. *Nucleosides Nucleotides* **1993**, *12*, 237–243. (n) Huang, C.-Y.; Cushman, C. D.; Miller, P. S. *J. Org. Chem.* **1993**, *58*, 5048–5049.

(2) This nucleoside was prepared from 3',5'-di-*O*-acetyl-2'-deoxyuridine according to the procedure of Divakar, K. J.; Reese, C. B. *J. Chem. Soc.* **1982**, 1171–1176.

(3) 3',5'-Diacetyl-**1** was isolated in 62% yield following silica gel column chromatography. The mass spectrum, MH⁺ 404.2, and ¹H NMR spectrum were consistent with the structure of this compound.

(4) Brown, T.; Brown, D. J. S. *Oligonucleotides and Analogues. A Practical Approach*; IRL Press: Oxford, 1991; pp 1–24. The oligomer was deprotected by treatment with concentrated ammonium hydroxide/pyridine (1:1 v/v) at 50 °C for 10 h and purified by C-18 reversed-phase high-performance liquid chromatography. The oligomer gave the expected ratios of nucleosides when digested with a combination of snake venom phosphodiesterase and bacterial alkali phosphatase.

(5) Pilch, D. S.; Levenson, C.; Shafer, R. H. *Proc. Natl. Acad. Sci. U.S.A.* **1990**, *87*, 1942–1946.




Figure 1. Temperature versus *A*₂₆₀ profiles of I-II-III(1-X·Y) measured at pH 7.0 in a buffer containing 0.1 M sodium chloride, 20 mM magnesium chloride, and 50 mM 3-(*N*-morpholino)propanesulfonic acid (MOPS) buffer. The oligomer concentration was 1 μM per strand, and the solutions were heated from 0 °C to 60 °C at a rate of 0.5 deg/min. Base pairs X·Y in II-III are shown at the right of each curve, and the curves are offset for clarity.





Figure 2. Partial 300-MHz ¹H NMR spectra of **1** in DMSO-*d*₆.

I-II-III(1-G-C). In the case of I-II-III(1-C-G), a broad biphasic transition was consistently observed between 24 °C and 44 °C.

Hydrophobic interactions between the pyridinyl ring of **1** and neighboring bases may contribute to triplex formation by **1**. In the case of I-II-III(1-G-C), hydrogen bonding between the N-3 (protonated) and N-4 positions of the amino tautomer of the cytosine ring of **1** and G of the G-C base pair appears to be sterically feasible. The observed reduction in *T*_m of I-II-III(1-G-C) to 15 °C at pH 8.0 is consistent with such a hydrogen-bonding scheme. The more stable I-II-III(1-A-T) and I-II-III(1-C-G) triplexes may involve additional hydrogen-bonding interactions, as shown schematically below. Both triads invoke an unusual imino



tautomeric form of **1**. This tautomer provides a pattern of hydrogen bond donor and acceptor groups which would allow

formation of two hydrogen bonds with the C·G base pair and three hydrogen bonds with the A·T base pair. Only a single hydrogen bond can be drawn between the pyridinyl amino group of **1** and the O-6 of G or the O-4 of T if **1** is in the amino tautomeric form. This hydrogen-bonding scheme could account for the higher T_m of I·II·III(1·A·T) relative to that of I·II·III(T·A·T), a triplex whose third strand employs two hydrogen bonds per base triad and melts at 22 °C at pH 7.0.⁶

Support for the existence of the imino tautomeric form comes from examination of the ¹H NMR and UV spectra of **1**. As shown in Figure 2, resonances corresponding to H-5 of cytosine and the Py-H3 of the pyridinyl ring are unusually broad at 22 °C but appear as sharp doublets at 67 °C.⁷ Such broadening could be due to restricted rotation about the C⁴-N⁴ bond caused by formation of the imino tautomer of **1**. Similar broadening was not observed for O⁴-(3-aminophenyl)-2'-deoxyuridine (**2**), an analog of **1** which cannot tautomerize. The UV absorption maxima of **1**, 288 and 327 nm, appear at longer wavelengths relative to those of deoxycytidine, 270 nm, and diaminopyridine, 308 nm.⁸ This red shift is consistent with conjugation between the cytosine and pyridine rings, which could occur as a result of tautomerization. The UV spectrum of **2**, on the other hand, does not show a similar red shift.

(6) Miller, P. S.; Cushman, C. D. *Biochemistry* 1993, 32, 2999-3004.

(7) The proton resonances in **1** were completely assigned using 2-D COSY techniques.

(8) UV spectra were recorded in acetonitrile/water (1:1 v/v) at pH 7.

The broad biphasic transition observed for I·II·III(1·C·G) suggests the presence of more than one distinct type of triplex. Recent studies by Koshlap *et al.* show that the nonnatural base 4-(3-benzamido)phenylimidazole specifically recognizes T·A and C·G base pairs as a result of intercalation.⁹ Intercalation may also play a role in triplex formation by base analog **1**.

Our results suggest that **1** and similar base analogs which can potentially contact both bases of a base pair might be used to extend the types of duplex sequences recognized by third-strand oligopyrimidines. Experiments to explore this possibility and to more completely characterize the interactions of **1** are currently in progress.

Acknowledgment. This research was supported by a grant from the National Institutes of Health, GM45012. The NMR studies were performed in the Biophysics NMR Facility at the Johns Hopkins University, which was established by a grant from the National Institutes of Health (GM 27512) and a Biomedical Shared Instrumentation Grant (1S10-RR06261-0). C.-Y.H. is a GENTA, Inc. postdoctoral fellow in the Department of Biochemistry. We wish to thank Mr. David M. Noll for help in obtaining the ¹H NMR spectra, Dr. Tina L. Trepane for help in obtaining the CD spectra, and Dr. David Shortle for use of the CD spectropolarimeter.

(9) Koshlap, K. M.; Gillespie, P.; Dervan, P. B.; Feigon, J. *J. Am. Chem. Soc.* 1993, 115, 7908-7909.